|
시장보고서
상품코드
2131152
사쿠비트릴 나트륨 시장 규모, 점유율, 성장 분석 : 제품 유형별, 용도별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Sacubitril Sodium Market Size, Share, and Growth Analysis, By Product Type (API, Pharmaceutical Formulation), By Application (Heart Failure Treatment, Research), By End User, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 사쿠비트릴 나트륨 시장 규모는 2024년에 8억 9,000만 달러로 평가되며, 2025년 9억 6,298만 달러에서 2033년까지 18억 899만 달러로 확대할 전망이며, 예측 기간(2026-2033년)에 CAGR 8.2%로 성장할 것으로 전망되고 있습니다.
네프릴라신 억제제로서의 역할과 심부전 치료시 발사르탄과의 병용으로 알려진 전 세계 사쿠비트릴 나트륨 시장은 심혈관계 의약품 포트폴리오에서 중요한 위치를 차지하는 존재로 변모했습니다. 이러한 성장은 임상 시험의 긍정적인 결과에 힘입어, 효과적이며 사망률을 낮추는 치료법에 대한 수요 증가를 반영하고 있습니다. 시장 확대는 성과 기반 지불 모델을 중시하는 보험 환급 환경의 변화에 의해 더욱 가속화되고 있으며, 조기 처방 도입이 촉진되고 있습니다. 이러한 추세는 의료제도가 재입원 감소를 목표로 하여 보험사의 비용 절감으로 이어진다는 점에서 특히 두드러집니다. 또한 AI를 활용한 데이터 분석을 통해 다양한 데이터 소스를 통합하여 수요 예측의 정확도가 향상되었으며, 제조사는 실시간 시장 동향에 따라 공급망과 생산을 최적화할 수 있게 되었습니다. 그 결과, 제품의 가용성이 확대되고 공급 지연이 완화되고 있습니다.
전 세계 사쿠비트릴 나트륨 시장의 성장 요인
의료 종사자와 환자 모두의 심부전에 대한 의식의 향상는 적시 진단과 권장 치료 프로토콜의 도입을 촉진하고 있으며, 사쿠비트릴 나트륨은 유병률 감소에 효과적인 선택지로 지지받으며 다양한 의료 환경에서 처방 범위가 확대되고 있습니다. 의료 종사자들은 안지오텐신 수용체 차단 요법에 더해 네프릴리신 억제의 이점을 점차 인식하게 되었으며, 그 결과, 박출률이 저하된 환자에 대한 치료 지침에 사쿠비트릴 나트륨이 더 널리 포함되고 있습니다. 이러한 추세는 환자의 삶의 질(QOL) 향상과 장기적인 건강 결과 개선에 있으며, 이 약물의 중요성을 강조하기 위한 인식 제고 활동에 의해 더욱 지원되고 있습니다.
전 세계 사쿠비트릴 나트륨 시장의 성장 저해 요인
전 세계 사쿠비트리일 나트륨 시장은 주로 기존 제네릭 심부전 치료제에 비해 가격이 비싸다는 점에 기인한 중대한 제약에 직면해 있으며, 이는 의료비 지불 기관에게 예산상 과제가 되고 있습니다. 이 때문에 약물 채택 위원회는 사용 제한을 두거나 사전 승인을 의무화하는 경우가 많으며, 특히 비용에 민감한 시장에서는 치료 시작 지연이나 환자의 접근 제한으로 이어질 가능성이 있습니다. 또한 보험사는 금액 기반 계약에서 비용 대비 효과가 더 높은 대체 약물을 우선시하는 경우가 있으며, 이로 인해 의료 종사자들은 저가 옵션에 집중하도록 유도됩니다. 이러한 추세는 사쿠비트리ル 나트륨의 채택을 저해할 뿐만 아니라, 제약사가 보험 급여를 확보하기 위해 건강 경제학적 측면에서 상당한 이점을 입증하도록 강요하고 있습니다.
전 세계 사쿠비트릴 나트륨 시장의 동향
전 세계 사쿠비트릴 나트륨 시장은 정밀 심장 치료에 대한 관심이 높아지는 것을 배경으로 견고한 성장을 달성하고 있습니다. 이러한 추세는 의료 제공자가 유전자 프로파일링 및 바이오마커 데이터를 활용하여 개별 환자에게 맞춤화된 치료를 제공하는 등, 개인 맞춤형 치료 전략으로의 전환을 부각시키고 있습니다. 사쿠비트릴 나트륨의 도입은 대상 집단에서 그 유효성을 입증하는 공동 연구 노력에 의해 더욱 촉진되고 있으며, 이를 통해 지불 기관은 가치 기반 환급 모델을 수용하도록 유도되고 있습니다. 그 결과, 제약사들은 차별화된 시장 기회를 활용할 수 있는 위치에 놓이게 되었으며, 치료 성과를 향상시키고 전 세계 다양한 헬스케어 시스템에서 접근성을 확대함으로써, 궁극적으로 심혈관 질환 관리 분야에서 보다 효과적이고 환자 중심의 접근 방식을 촉진하게 될 것입니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 사쿠비트릴 나트륨 시장 규모 : 제품 유형별
세계의 사쿠비트릴 나트륨 시장 규모 : 용도별
세계의 사쿠비트릴 나트륨 시장 규모 : 최종사용자별
세계의 사쿠비트릴 나트륨 시장 규모 : 유통 채널별
세계의 사쿠비트릴 나트륨 시장 규모 : 지역별
세계의 사쿠비트릴 나트륨 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSAGlobal Sacubitril Sodium Market size was valued at USD 890.0 Million in 2024 and is poised to grow from USD 962.98 Million in 2025 to USD 1808.99 Million by 2033, growing at a CAGR of 8.2% during the forecast period (2026-2033).
The global sacubitril sodium market, known for its role as a neprilysin inhibitor and in combination with valsartan to treat heart failure, has transitioned to a significant player in the cardiovascular drug portfolio. Its growth reflects increasing demand for effective, mortality-reducing treatments, underpinned by positive clinical trial outcomes. The market's expansion is further propelled by an evolving reimbursement landscape favoring outcome-based payment models, encouraging early prescription adoption. This trend is particularly evident as healthcare systems aim to reduce hospital readmissions, generating cost savings for insurers. Additionally, AI-driven data analytics enhances demand forecasting by integrating diverse data sources, enabling manufacturers to optimize supply chains and production in response to real-time market signals, thereby expanding access and reducing latency.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sacubitril Sodium market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Sacubitril Sodium Market Segments Analysis
Global sacubitril sodium market is segmented by product type, application, end user, distribution channel and region. Based on product type, the market is segmented into API and Pharmaceutical Formulation. Based on application, the market is segmented into Heart Failure Treatment and Research. Based on end user, the market is segmented into Pharmaceutical Companies, Research Institutes and Hospitals. Based on distribution channel, the market is segmented into Direct Sales and Distributors. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Sacubitril Sodium Market
The increasing recognition of heart failure by both healthcare professionals and patients promotes timely diagnosis and the integration of recommended treatment protocols, making sacubitril sodium a favored choice for alleviating morbidity and broadening its prescribing landscape in various healthcare environments. Medical practitioners are progressively acknowledging the benefits of neprilysin inhibition alongside angiotensin receptor blockade, resulting in the wider incorporation of sacubitril sodium into therapeutic guidelines for individuals with reduced ejection fraction. This trend is further supported by educational efforts aimed at emphasizing its significance in enhancing patients' quality of life and improving long-term health outcomes.
Restraints in the Global Sacubitril Sodium Market
The Global Sacubitril Sodium market faces significant restraints primarily due to its premium pricing compared to older generic heart failure medications, which creates budgetary challenges for healthcare payers. This often leads formulary committees to implement restrictions on utilization or mandate prior authorization, potentially delaying therapy initiation and limiting patient access, particularly in markets sensitive to costs. Furthermore, insurance providers may prefer more cost-effective alternatives within value-based contracts, encouraging healthcare professionals to focus on lower-priced options. This dynamic not only hinders the adoption of sacubitril sodium but also compels manufacturers to substantiate substantial health-economic benefits to secure reimbursement.
Market Trends of the Global Sacubitril Sodium Market
The Global Sacubitril Sodium market is experiencing robust growth driven by an increasing focus on precision cardiology. This trend highlights the shift towards personalized treatment strategies, as healthcare providers utilize genetic profiling and biomarker data to tailor therapies for individual patients. The adoption of sacubitril sodium is further supported by collaborative research efforts that validate its efficacy in targeted populations, prompting payers to embrace value-based reimbursement models. As a result, manufacturers are positioned to exploit differentiated market opportunities, enhancing therapeutic outcomes and expanding access across diverse healthcare systems globally, ultimately fostering a more effective and patient-centered approach to cardiovascular care.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Sacubitril Sodium Market Size by Product Type & CAGR (2026-2033)
- Market Overview
- API
- Pharmaceutical Formulation
Global Sacubitril Sodium Market Size by Application & CAGR (2026-2033)
- Market Overview
- Heart Failure Treatment
- Research
Global Sacubitril Sodium Market Size by End User & CAGR (2026-2033)
- Market Overview
- Pharmaceutical Companies
- Research Institutes
- Hospitals
Global Sacubitril Sodium Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Direct Sales
- Distributors
Global Sacubitril Sodium Market Size by Region & CAGR (2026-2033)
- Market Overview
- North America
- Europe
- Asia-Pacific
- Others
Global Sacubitril Sodium Market Size & CAGR (2026-2033)
- North America (Product Type, Application, End User, Distribution Channel, Region)
- US
- Canada
- Europe (Product Type, Application, End User, Distribution Channel, Region)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Product Type, Application, End User, Distribution Channel, Region)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Product Type, Application, End User, Distribution Channel, Region)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Product Type, Application, End User, Distribution Channel, Region)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MSN Laboratories Pvt. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurobindo Pharma Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Laurus Labs Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hetero Labs Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Lifesciences Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Intas Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alembic Pharmaceuticals Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alkem Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shilpa Medicare Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Divi's Laboratories Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Macleods Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biocon Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lee Pharma Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aspen Pharmacare Holdings Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
